Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
about
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection.Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan.Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.Optimal management of patients with chronic hepatitis C and comorbidities.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer developmentThe spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues.Screening therapeutic targets of ribavirin in hepatocellular carcinoma.HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation
P2860
Q30391932-AE180802-0517-46CC-B27A-CAF9DA24BF76Q35270193-3B05955C-2F6D-4B73-AC1B-D9FDA3603366Q37207070-761C237E-72DC-465A-AF10-7348D352174BQ37328650-F502FE4A-6B9A-422C-BBA7-E6BC062C04DAQ37654521-384B1EA6-6578-4DF0-ADAD-06FCD87EB326Q38160511-3E9CE1E2-F2B1-4ECB-9763-91CD317F59DCQ38295819-D2AE4C23-FBE0-4C24-84E9-3B8F3B97F620Q38515906-B0F8010B-7473-4340-B9C0-8241AF2B2C6FQ41412095-D8298B2D-2529-4999-815B-FBB2FE5DA9C9Q42201264-C0982752-1350-4963-8F33-6D7757AA97B0Q42683902-C2D6C941-B2BC-4D25-8FF9-E0ED49D2A820Q42746527-C5E7D005-C13C-432F-BB23-95EFB1F0B895Q54222473-23E2D3FC-EA99-493E-9B4E-1F49B1D5BC0DQ55331757-C21972E8-8816-4AAF-ACCE-A7D8D95119B8Q57066911-D1D0E594-BCD3-40DF-ACDF-86C70296A66B
P2860
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Treatment of patients with dua ...... lular carcinoma and mortality.
@en
Treatment of patients with dua ...... lular carcinoma and mortality.
@nl
type
label
Treatment of patients with dua ...... lular carcinoma and mortality.
@en
Treatment of patients with dua ...... lular carcinoma and mortality.
@nl
prefLabel
Treatment of patients with dua ...... lular carcinoma and mortality.
@en
Treatment of patients with dua ...... lular carcinoma and mortality.
@nl
P2860
P50
P1433
P1476
Treatment of patients with dua ...... llular carcinoma and mortality
@en
P2093
Wen-Yi Shau
Yu-Tseng Chu
P2860
P304
P356
10.1136/GUTJNL-2012-304370
P407
P577
2013-05-15T00:00:00Z